Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02439957 · ClinicalTrials.gov registry record · Phase 3
A Phase 3 Study of Brincidofovir Versus Valganciclovir for the Prevention of Cytomegalovirus
A Phase 3 study, sponsored by Jazz Pharmaceuticals.
- Terminated
- Registry status
- Phase 3
- Development phase
- 6
- Enrollment target
NCT02439957: Clinical Trial Phase 3 study, sponsored by Jazz Pharmaceuticals.
NCT02439957 is a Phase 3 study that was terminated before completion, run by Jazz Pharmaceuticals. The registered enrollment target is 6 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02439957, a Phase 3 study, was terminated before completion, sponsored by Jazz Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 6 participants
- Enrollment target
Study Summary
This was a randomized, double-blind, double-dummy, parallel-group, multicenter study of the efficacy, safety, and tolerability of oral brincidofovir (BCV) versus valganciclovir for the prevention of cytomegalovirus (CMV) disease in CMV-seropositive kidney transplant recipients who received antilymphocyte induction therapy.
Primary Outcome
The incidence of CMV disease, which included CMV tissue-invasive disease and CMV syndrome, occurring anytime between randomization and Week 24 posttransplant (±14 days). The proportion of subjects who met this failure endpoint were to be compared between brincidofovir (BCV) and valganciclovir (vGCV) using an unadjusted 95% confidence interval (CI) of the absolute difference between groups (BCV minus vGCV). Number of failures and failure rates were to be presented for each treatment. If the uppe
Interventions
- DRUG Valganciclovir
- DRUG Brincidofovir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2015-09 |
| Est. Completion | 2016-07-31 |
| Phase | Phase 3 |
Why NCT02439957 stopped before completion
NCT02439957 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 2 interventions - of which Valganciclovir is the first listed.
NCT02439957 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02439957 about?
NCT02439957 is a clinical study titled "A Phase 3 Study of Brincidofovir Versus Valganciclovir for the Prevention of Cytomegalovirus". This was a randomized, double-blind, double-dummy, parallel-group, multicenter study of the efficacy, safety, and tolerability of oral brincidofovir (BCV) versus valganciclovir for the prevention of cytomegalovirus (CMV) disease in CMV-seropositive kidney transplant recipients who received antilymph...
What is the current status of trial NCT02439957?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 6 participants. The study started on 2015-09. Estimated completion is 2016-07-31.
What interventions are being tested in trial NCT02439957?
The interventions under investigation include: Valganciclovir (DRUG), Brincidofovir (DRUG).
Who is sponsoring clinical trial NCT02439957?
This trial is sponsored by Jazz Pharmaceuticals, which has 128 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02439957's enrollment target sits among peer trials
6 1995th of 2000 higher than 4 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia